January 26, 2026 | AI in Healthcare | Strategic Investment & Market Expansion
OpenEvidence, the AI platform often described as “ChatGPT for doctors,” has closed a $250 million funding round, propelling its valuation to approximately $12 billion. This milestone underscores the surging adoption of AI-powered clinical decision support tools in U.S. healthcare.
The company’s technology is now reportedly used by roughly 40% of U.S. physicians, enabling clinicians to quickly access evidence-based insights, streamline patient care decisions, and improve treatment precision across diverse therapeutic areas.
Why This Matters
The rapid adoption of OpenEvidence reflects a broader shift in healthcare: AI is moving from pilot projects to core clinical workflows, transforming how doctors diagnose, treat, and manage patients.
- Efficiency Gains: Physicians save time synthesizing research and guidelines, freeing capacity for patient care.
- Evidence-Based Decisions: The platform integrates real-world data, clinical trials, and guidelines to support more precise interventions.
- Market Validation: A $12 billion valuation signals strong investor confidence in AI’s role in shaping the future of healthcare delivery.
Strategic Insight
OpenEvidence’s latest funding round positions it to:
- Expand adoption across hospitals, clinics, and telehealth platforms
- Accelerate integration with electronic health record (EHR) systems
- Invest in advanced AI capabilities for predictive analytics, treatment planning, and patient outcomes
For the healthcare ecosystem, this development signals that AI is no longer ancillary—it is becoming a trusted extension of clinical expertise, potentially reshaping physician workflows and patient care standards across the U.S.
Key Takeaway:
OpenEvidence’s $12 billion valuation is more than a financial milestone—it reflects a tipping point in healthcare, where AI is moving from promise to practical, large-scale clinical impact.
By